Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First

Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD  |  Issue: October 2021  |  October 13, 2021

Simpler instruments, such as the Patient Experienced Symptom State (PESS), may be used to screen for patients in need of more detailed impact evaluation.22

With the dual-target proposal, we seek to ensure the patient’s perspective is reinforced as the central target of disease management. Controlling the disease process, the current target, is an important means to that end, but not a sufficient warranty, as seen above.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Empathy

The health professional’s goal is to serve the patient’s interests in the best possible way.

The patient knows things the clinician often ignores: the symptoms, their intensity and their relative impact on their quality of life. Similarly, the clinician knows things the patient may ignore or be unaware of: that controlling the disease process is pivotal to helping the patient achieve their quality-of-life goals and to prevent irreversible structural and functional damage.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This lack of mutual awareness may lead to unintended consequences, such as the use of stronger medications than the patient feels is warranted or the withdrawal of agents that seem to be working. Because neither the clinician nor the patient wants this to be the end result of the encounter, we must seek solutions that limit the like­lihood they will occur.

We believe the treatment target should incorporate the improvement of the patient’s experience beyond mere disease control. That imposes the requirement on the clinician to understand the needs and desires of the patient through active listening in a context that rheuma­tologists master exceedingly well: true doctor-patient relationships.

Active listening requires not just time, but presence. Presence is when we engage our patients without interrupting, judging or minimizing. It is more than clock time, and although it may appear ineffable, patients know when the doctor is present during their visit. As Ronald Epstein points out in his book, Attending, doctors often don’t do this well.23

A study from the Mayo Clinic supports this: The researchers qualitatively analyzed patients who were discordant in their global response with their providers’ findings. Such patients generally felt they weren’t being listened to and experienced a gap in empathy.24

Nothing will assist us more in our effort to achieve disease control and address the patient’s goals than placing the patient’s views and experiences at the center of the target. The dual-target strategy may play an important role in framing and promoting this path.


Ricardo J.O. Ferreira, RN, PhD, is a specialist nurse and researcher at the Rheumatology Department of Centro Hospitalar e Universitário de Coimbra, and researcher at Health Sciences Research Unit: Nursing (UICiSA:E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal. He currently serves as chair of the EULAR Health Professionals in Rheumatology (HPR) Committee.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsPatient PerspectiveRheumatoid ArthritisSpeak Out Rheum Tagged with:Disease Activity Score (DAS)patient centerednessshared decision makingSpeak Out RheumatologyTreat-to-Target

Related Articles

    Remission Definitions in RA: Common Questions & Implications for Clinical Practice

    May 5, 2022

    A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.

    How Does Health Literacy Affect the Patient Global Assessment?

    May 8, 2019

    For RA patients, a low score on the patient global assessment of disease activity as measured by a visual analog scale (PGA-VAS) is necessary to confirm remission. However, limited patient health literacy combined with the complexity of the scale may result in discrepancies between the PGA-VAS and provider assessments of disease activity. New research examined the patient perspective on the PGA-VAS and its connections to health literacy and disease state…

    Target Remission

    March 1, 2007

    Strategies to identify and track remission in your RA patients

    New Criteria for RA Remission

    February 12, 2011

    ACR and EULAR update 1981 criteria to reflect modern treatment options

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences